App-Quantinova.ai

Supporting European and worldwide cancer research with patient-derived xenografts

Emilie Vinolo - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC

Bruce E. Johnson - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral neuropathy

Pembrolizumab

A phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors

Grace K. Dy - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Durvalumab

Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma

Luigi Buonaguro - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cyclophosphamide

Utilizing image analysis to characterize an 8-plex immunofluorescence immune checkpoint biomarker panel within the tumor tissue microenvironment

Alison L. Bigley - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Combining automated image analysis and digital spatial profiling to investigate prognostic immune signatures in clear cell renal cell carcinoma

Raffaele De Filippis - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

N/A

Fatty acid binding protein 7 regulates beige fat-like differentiation of breast cancer cells and thermogenesis

Masahiro Kawashima - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

Apostolia M. Tsimberidou - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Investigating mechanisms of tolerance to APOBEC3B upregulation in cancer

Caitlin M. McCarthy - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

TP53

Annexin-A1 as a potential therapeutic target for solid tumors

Fiona C. Dempsey - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors

Zhen Lu - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade serous ovarian cancer

Paclitaxel

Identification of cancer-specific synthetic lethal genes as novel therapeutic targets

Lalchung Nunga - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Medulloblastoma

N/A

Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC)

Luis Paz-Ares - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

The landscape of somatic substitutions in the repetitive genome across cancer types

Maxime Tarabichi - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Phenotyping tumor infiltrating lymphocytes (TILs) in vitro using 3D cell models and advanced flow cytometry

Donald Weldon - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Analysis of clinical BRCA1/2 reversions identifies hotspot mutations and predicted neoantigens associated with therapy resistance

Stephen Pettitt - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

LRG1 blockade normalizes tumor vasculature and improves efficacy of chemotherapy

Camilla Pilotti - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Investigating determinants of sensitivity to ATR inhibition, as predictive biomarkers to single agent ATR inhibitor, VE-821, in ovarian cancer

Alice Mary Bradbury - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade serous ovarian cancer

VE821

Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice

Alexandra Drakaki - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Techniclone TNT

Predicting drug effects on breast cancer cell shapes by converging image and transcriptomic profiles

Zheng Yin - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Breast cancer

N/A

Filters

45280 Abstracts